Abstract We have previously reported that nltrlc oxide (NO) plays an important role m protecting the renal vasculature from acute norepmephrme-induced vasoconstnctlon The purpose of this study was to determine the importance of this mteractlon between NO and norepmephrme In long-term control of renal hemodynamlcs and arterial pressure To achieve this goal, we examined the effects of an u&arena1 mfuslon of norepmephrme (NE) (0 1 pg kg-' mm-') for 7 days In conscious, chromcally instrumented control dogs and In dogs pretreated with a synthesis mhlbltor, L-NAME (3 pg kg-' nun-' mtrarenally) Both groups of dogs also received captoprll (15 pg kg-' mu-') plus anglotensm II mtravenously to clamp the remn-anglotensm system throughout the protocol In control dogs (n=6), mtrarenal mfuSian of NE decreased renal plasma flow by 9% (134+ 10 to 122? 14 mL/rmn) and glomerular filtration rate by 16% (4924 to 4125 mL/mm) while having no effect on mean artenal pressure (lOOt3 to 9854 mm Hg) In marked contrast, in dogs pretreated with intrarenal L-NAME (n=9), NE decreased renal plasma flow by 37% (12928 to 8 1 + 16 mL/mm) and glomerular filtration rate by 32% (4723 to 322.5 mL/mm) whde mcreasmg The renal hemodynamlc and possibly hypertensive responses to chronic renal adrenerglc stlmulatlon may also be influenced by vasodllator counterregulatory mechanisms. Although adrenerglc stlmulatlon results in rather large short-term reductions m renal blood flow and GFR, these changes in renal hemodynamlcs are not sustained chronically despite contmuous mtrarenal administration of norepinephrme 7 Although the exact mechanisms for the escape from adrenerglcally medlated renal vasoconstrlctlon may be multiple, it 1s likely that local vasodllator factors such as nitric oxide may be involved 8-13 Consistent with this suggestion are results from previous studies from our laboratory mdtcatmg that nitric oxide plays an important role m modulating the short-term vasoconstrlctor actlons of anglotensm II and norepmephrme. 14-16 However, Committee Surgery was performed under aseptic condltlons The preanesthehc agents sodium thlopental(5%) and atropme (1 5 mg IM) were given mitlally, followed by lsoflurane (1% to 2%) continued throughout surgery Tygon catheters were implanted In the abdominal aorta, distal to the ongms of the renal arteries, via the femoral arteries for arterial pressure momtormg and blood sampling Tygon catheters were also implanted m the vena cava via the femoral veins for intravenous mfusion of various substances A unilateral nephrectomy was then performed on the right kidney In the left renal artery, a Tygon catheter was implanted as previously described by Herd and Barger 19 All catheters were tunneled subcutaneously, exteriorized between the scapulae, and 
R enal adrenerglc stlmulatlon via mtrarenal infusion
of norepmephrme results in vasoconstriction, mcreased tubular reabsorption of sodium, enhanced remn, and hypertension. 132 The effects of noreplnephnne on renal hemodynamics, sodium excretion, and artenal pressure are achieved directly by actlvatlon of Ly-adrenerglc receptors and mdlrectly by enhanced anglotensm II formation. 1.1-7 Indeed, a recent study by Remhart et a17 demonstrated that anglotensm II plays a critical role m mediating the chronic hypertension associated with levels of adrenerglc stlmulatlon that have little chronic mfluence on renal hemodynamlcs
The renal hemodynamlc and possibly hypertensive responses to chronic renal adrenerglc stlmulatlon may also be influenced by vasodllator counterregulatory mechanisms. Although adrenerglc stlmulatlon results in rather large short-term reductions m renal blood flow and GFR, these changes in renal hemodynamlcs are not sustained chronically despite contmuous mtrarenal administration of norepinephrme 7 Although the exact mechanisms for the escape from adrenerglcally medlated renal vasoconstrlctlon may be multiple, it 1s likely that local vasodllator factors such as nitric oxide may be involved 8-13 Consistent with this suggestion are results from previous studies from our laboratory mdtcatmg that nitric oxide plays an important role m modulating the short-term vasoconstrlctor actlons of anglotensm II and norepmephrme. 14-16 However, From the Department of Physiology and Blophyslcs, Umverslty of Mlssisslppl Medical Center, Jackson, Miss
Correspondence to Joey P Granger, PhD, Department of Physlology and Biophysics, Umverslty of Miss~sslppl Medical Center, 2500 N State St, Jackson, MS 39216-4505 E-mall JPG@ fiona umsmed edu 0 1997 Amencan Heart Assoclatlon, Inc whether mtrlc oxide plays a role m modulating the long-term actions of norepmephrme 1s uncertain, since we have recently reported that the long-term actions of angiotensm II on renal function and arterial pressure are not potentlated by chronic nitric oxide synthesis blockade. L7,18 Therefore, the objective of this study was to quantltate the long-term role of nitric oxide m modulating the chronic renal hemodynamlc and hypertensive actions of renal adrenerglc stimulation via mtrarenal norepmephrine mfuslon To achieve this objective, we determined the long-term effects of mtrarenal norepmephrme mfuslon on renal function and arterial pressure regulation m dogs with or without renal nitric oxide synthesis blockade with L-NAME
Methods

Animal Preparation
Experiments were performed m 15 conscious, chromcally mstmmented female mongrel dogs weighing 18 to 21 kg Surgery and care of animals were conducted according to the National Institutes of Health gmdehnes for the care and use of ammals and with the approval of the Institutional Animal Care and Use Committee Surgery was performed under aseptic condltlons The preanesthehc agents sodium thlopental(5%) and atropme (1 5 mg IM) were given mitlally, followed by lsoflurane (1% to 2%) continued throughout surgery Tygon catheters were implanted In the abdominal aorta, distal to the ongms of the renal arteries, via the femoral arteries for arterial pressure momtormg and blood sampling Tygon catheters were also implanted m the vena cava via the femoral veins for intravenous mfusion of various substances A unilateral nephrectomy was then performed on the right kidney In the left renal artery, a Tygon catheter was implanted as previously described by Herd and Barger 19 All catheters were tunneled subcutaneously, exteriorized between the scapulae, and GFR = glomerular filtration rate L-NAME = N-mtro-L-argmme methyl ester MAP = mean arterial pressure RPF = renal plasma flow RVR = renal vascular resistance After recovery from surgery, dogs were housed m mchvidual metabolic cages and fitted with harnesses that contained pressure transducers mounted at heart level Arterial catheters were connected to the pressure transducer, and 24-hour MAP, pulsatile pressure, and heart rate were monitored via an analog-to-digital data collection system The analog signal was sampled 60 times/h and recorded on a personal computer For data analysis, all pressure and heart rate data were averaged over an l&hour period excluding the mamtenance period m the mommg The venous catheter was connected to a peristaltic pump (Wiz, ISCO Inc) for contmuous infusion of solutions throughout the study Isotonic saline was contmuously infused mtravenously at 450 mL/d to mamtam the total sodium intake at 70 mEq/d All solutions were first pumped through a disposable filter (Milhpore) to prevent air bubbles and possible contaminants from entering the venous system The filters were changed frequently throughout the study as needed Rnally, the renal artery catheter was connected to a 60-mL syringe filled with lsotomc saline, which was infused at 1 875 mL/h Again, a disposable filter was used to prevent air bubbles and contaminants from entermg the kidney The infusion tubing and transducer hnes were protected by a flexible vacuum hose that was attached to the harness The dogs were allowed to move freely m the cage but were unable to turn completely around
Daily Maintenance and Data Collection
Daily maintenance of the dogs was performed m the morning between 8 and 10 AM Dogs were fed with a sodium-deficient diet (WD, Hill's Pet Products) that provided 2 to 3 mEq of sodmm and 65 mEq of potassium per day and allowed free access to water Dicloxicilhn (2x250 mg) and Sulfatrim (2x400 mg) were given orally for prophylaxis Urme volume and electrolyte concentrations, water and saline intake, and body temperature were measured Fresh solutions for intravenous and mtrarenal mfusions were prepared, catheters were flushed with heparmized saline, and cages were cleaned Arterial pressure and heart rate data from the previous day were stored and analyzed
Experimental Protocol
All dogs were divided mto two groups, and arterial pressure, heart rate, and renal function were determined before, durmg, and after mtrarenal norepmephnne mfusion Group I (vehicle) consisted of six dogs with mtrarenal Isotonic sahne vehicle treatment Group II (L-NAME) consisted of nme dogs with mtrarenal NO synthesis blocked, established by infusion of L-NAME via the renal artery at 3 yg kg-' mu-' We have previously shown that this dose of L-NAME infused via the renal artery blocks endothehum-dependent vasochlatation m the dog 10 I4 15 20 In both groups, the remn-angiotensm system was clamped by mfusing captoprll ( 15 pg kg-' mu-') plus anglotensm II (0 5 ng kg-' mm-') mtravenously throughout the study to assess the actions of norepmephrme infusion m the absence of changes m endogenous ANG II formation The dogs were allowed to become acclimated to then daily routine, and a 7-day pretreatment period occurred before the control data were obtained. After a 7-day control period, norepmephrme (Levophed, Winthrop Pharmaceuticals) was contmuously infused mtrarenally for 7 days at a rate of 0 1 pg kg-' rnn-' A 7-day recovery penod from norepmephrme followed Renal function was determined on days 1, 3, 8, 11, 14 , and 20 of the study GFR and RPF were determined using the single-injection technique as previously described by Hall et al 21
Results
Fig 1 illustrates MAP and heart rate before, during, and after m&arena1 mfuslon of norepmephrme m dogs pretreated with salme vehicle or L-NAME In vehlcle-pretreated dogs, MAP averaged 10023 mm Hg under basal condltlons, 98+4 mm Hg during 7 days of mtrarenal norepmephrme mfuslon, and 95 t4 mm Hg during the recovery phase of the experiment. In contrast to the vehlcletreated dogs, MAP m dogs pretreated with L-NAME Increased slgruficantly m response to 7 days of mtrarenal norepmephnne MAP m dogs pretreated with L-NAME averaged 10425 mm Hg durmg basal condltlons and mcreased to 110 to 113 mm Hg (PC 05) during norepinephrme mfuslon MAP then decreased to 103k-8 mm Hg after norepmephrme infusion was stopped In both groups of dogs, heart rate remained relatively constant throughout the experiment Heart rate was an average of 73k.5 bpm during basal conditions, 74k7 bpm dunng norepmephrme infusion, and 7626 bpm durmg recovery m dogs pretreated with salme vehicle In dogs pretreated with L-NAME, heart rate was an average of 6225 bpm durmg control conchtlons, 5825 bpm during norepmephnne mfusion, and 6325 bpm m recovery Fig 2 shows the renal hemodynamlc response during basal conditions, m response to an mtrarenal mfusion of norepmephrme, and during recovery m both groups of dogs In saline-pretreated dogs, GFR was 4924 mL/mm during basal conditions, tended to decrease to 41-~5 mWmm in response to norepmephrme mfusron, and then began to return toward basal values (43~3 mL/mm) during recovery In contrast to the control dogs, norepmephrme caused a marked and significant decrease m GFR m dogs pretreated with L-NAME Durmg basal conditions, GFR in the L-NAME-pretreated dogs was 4723 mL/mm and decreased by 32% to 3225 mL/rmn (P< 05) durmg the norepmephnne mfuslon period GFR then returned toward basal levels (43+-3 mL/mm) dunng recovery Similarly, the RPF response to norepmephrme was markedly and significantly enhanced m dogs pretreated wtth L-NAME. In saline-pretreated dogs, RPF was 134t 10 mL/mm during basal condition, 122?14 mL/mm (P< 05) m response to norepinephnne, and 12 12 13 mL/min during the recovery period. In dogs pretreated with L-NAME, RPF was 12928 mL/mm under basal conditions, decreased by 37% to 812 16 mL/mm (P< 05) after norepmephrme mfusron, and returned toward basal values during the recovery period (11527 mL/mm) The RVR response to norepinephrme was also markedly enhanced m dogs pretreated with L-NAME. In saline-pretreated dogs, RVR was 1.2450 32 mm Hg mL-'*mln-' during basal condlttons, 1 45+-O 32 mm Hg mL-' mn-' m response to norepmephrme, and 1 16tO 21 mm Hg*mL-' mn-' during the recovery pertod In dogs pretreated with L-NAME, RVR was 1 43?0 15 mm Hg mL-' mm-' under basal conditions, increased by 91% to 2 73? 10.05 mm Hg*mL-' min-' (P<.O5) after norepmephrme mfusion, and returned toward basal values durmg the recovery pertod (l-45+ 0.02 mm Hg mL-' + mn-')
Fig 3 
Discussion
Renal adrenerglc sttmulatlon via mtrarenal infusion of norepmephrme at a dose of 0.1 pg kg-' min-' results m rather large short-term reductions m renal blood flow and GFR; however, the changes m renal hemodynamlcs are usually not sustained chromcally despite continued admmistration of norepinephrme. 7 Although the exact mechanisms for the escape from adrenerglcally mediated renal vasoconstriction may be multiple, the present study was performed to determine whether local vasodtlator factors such as nitric oxide are mvolved. As reported recently by Remhart et al,7 we found that chronic mtrarenal infusion of norepmephrme at a rate 0 10 yg kg-' + mm-' for 7 days resulted m only slight reductions m RPF and GFR. The new and important finding of the present study 1s that the chronic norepmephrine-induced decreases m renal hemodynamics are markedly enhanced m dogs m which renal nitric oxide synthesis is mhibited In marked contrast to the control dogs, mtrarenal mfuston of norepmephrme for 7 days produced sustained decreases m RPF (37%) and GFR (32%) m dogs pretreated with the mtr'c oxide synthesis mhibttor L-NAME These findings indicate that nltric oxide plays an important role m protecting the renal vasculature from the long-term vasoconstrtctor actions of norepmephrme Previous studies have indicated that nitric oxide plays an important role m protecting the renal vasculature from a variety of vasoconstrictors such as angtotensm II and endothelm.8-'1 Ito and colleagues8 were one of the first to demonstrate that nitrm oxide modulates the vasoconstrictor actions of angiotensm II m isolated preglomerular mlcrovessels of rabbits We have also reported an important short-term interaction between nitric oxide and angtotensm II m control of renal hemodynam'cs m consc'ous dogs '4~5 Interestmgly, Ito et al8 faded to demonstrate a role for mtnc oxide m modulatmg the vasoconstnctor actions of norepmephnne m isolated afferent arterioles of rabbits In contrast, we found m a recent study that the acute renal hemodynamic actions of norepmephrme were markedly enhanced m conscious dogs pretreated with the nitric oxide synthesis mhtbttor L-NAME. '6 These findings led us to propose that the escape from adrenergically mediated renal vasoconstr'ctton during contmuous long-term mtrarenal mfusron of norepmephrme may, m part, be due to nitric oxide However, whether mtr'c oxide played a role m modulatmg the long-term actions of norepmephrme was uncertain, since we have previously reported that the acute but not long-term actions of angiotensm II on renal function and arterial pressure were potent'ated by chrome mtnc oxide synthesis blockade. '73'8 In contrast to the ang'otensm II experiments, we found m the present study that the longterm renal hemodynamtc actions of norepmephrme are markedly potentiated by mtric oxide synthesis mhtbitton Thus, nitric oxide appears to play a greater role in modulating the chronic renal adaptation to the long-term effects of norepmephrme than ang'otensm II The exact reason why L-NAME does not potent'ate the long-term actions of angtotensm II is unclear but may be due to compensatory acttvation of other vasodtlatory systems such as renal prostano'ds Chronic renal adrenergrc stimulation via mtrarenal norepmephrme mfuston has been shown to cause hypertension through its effect to reduce renal sodmm excret'on or renal pressure natrmres's.4-6 Although the chronic hypertension induced by norepmephrme could be mediated through direct a-receptor st'mulation or mduectly v'a enhanced renin release, a recent study by Remhart et a17 demonstrated that anglotensin II plays a major role m mediating the hypertension induced by mtrarenal mfus'on of norepmephrme at a rate of 0 1 pg kg-' mu-' They found that when the renin-angiotensm system was clamped by convertmg enzyme mhibmon plus angiotensm II replacement, the chronic hypertensive effect of mtrarenal norepmephrine was completely abolished In our study, we also fixed the renm-angtotensm system constant m all of the dogs to examine the long-term interaction between mtrlc oxide and norepmephrme without the confounding effects of changes m angtotensm II formation Our results m the control dogs confirm the findings of Remhart et al in that we did not observe any hypertensive response to norepmephrme However, we did find that norepmephrme increased arterial pressure m dogs pretreated with L-NAME These data indicate that nitric oxide plays a role m modulatmg the long-term actions of norepmephrme on arterial pressure The enhanced blood pressure response to mtrarenal norepmephrme m the L-NAME-pretreated dogs was most likely related to the larger reductions m GFR and sodium excretion observed m this group of dogs
In the present study, mtrtc oxide synthesis within the kidney was inhibited by an mtrarenal mfusion of L-NAME at a rate of 3 /-lg kg-' mu-' We prevtously reported that this mtrarenal dose of L-NAME 1s sufficient to abolish endothehum-dependent vasodtlatatton induced by bradykmm m conscrous dogs 20 Furthermore, we reported that this intrarenal dose of L-NAME m consctous dogs decreased RPF by only 10% to 15% while having no effect on GFR 20 In the present study, however, RPF was not significantly different between the control group and the L-NAME-pretreated group The lack of stat'sttcal s'gmficance may be due to the vanab'hty of RPF between the two groups of dogs or possibly to the fact that the renal responses to L-NAME may be attenuated m ammals without an intact remn-ang'otensm system Despite no slgruficant drfferences m RPF or GFR between the control and L-NAM&pretreated dogs under basal conditions, mtrarenal rutnc oxide synthesis mlnbmon was very effective m enhancing the renal hemodynanuc response to norepmephrme.
In summary, we found that mtrarenal infusion of norepmephrme for 7 days in control dogs resulted in slight decreases m RPF and GFR while having no effect on MAP In marked contrast, m dogs pretreated with mtrarenal L-NAME, norepmephrme decreased RPF by 37% and GFR by 32% In addmon, the blood pressure response to norepmephrme was also enhanced m dogs with renal mtrtc oxide synthesis mhtbition. The results of this study demonstrate that mtnc oxide plays an important role m modulatmg the long-term actions of norepmephrme on renal function and arterial pressure The phys'ologtcal 'mphcation of this study 1s that the kidneys may become very susceptible to enhanced renal adrenergrc activity under pathophys'olog'cal diseases associated with endothehal dysfunction and decreased renal nitric oxide production
